Citigroup Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price

Key Points

• Citigroup cut its price target on Haemonetics from $75 to $70 and maintained a "neutral" rating, implying roughly a 16% upside from the current share price.
• Shares fell about 4% to $60.33 midday; analyst consensus is a "Moderate Buy" with an average target near $83.89, signaling higher upside than Citigroup's view.
• Haemonetics slightly beat quarterly EPS ($1.31 vs $1.27 est.) and revenue but reported revenue down 2.7% year-over-year, and guided FY2026 EPS to $4.90–$5.00 versus analyst expectations around $4.55.

Haemonetics (NYSE:HAE - Get Free Report) had its price objective lowered by analysts at Citigroup from $75.00 to $70.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a "neutral" rating on the medical instruments supplier's stock. Citigroup's price target would indicate a potential upside of 16.03% from the stock's current price.

Other equities research analysts have also issued research reports about the stock. Needham & Company LLC lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Monday, December 15th. BTIG Research restated a "buy" rating and set a $88.00 price objective on shares of Haemonetics in a research note on Friday, February 6th. Barrington Research set a $94.00 target price on Haemonetics in a research note on Friday, February 6th. CJS Securities upgraded shares of Haemonetics to a "strong-buy" rating in a research report on Thursday, December 11th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Haemonetics from $62.00 to $74.00 and gave the company a "neutral" rating in a research note on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Haemonetics has an average rating of "Moderate Buy" and an average target price of $83.89.

Haemonetics Stock Down 4.0%

Shares of HAE traded down $2.52 during midday trading on Wednesday, reaching $60.33. 212,128 shares of the company were exchanged, compared to its average volume of 886,467. Haemonetics has a 1-year low of $47.31 and a 1-year high of $87.32. The stock has a 50-day moving average price of $67.87 and a 200-day moving average price of $64.69. The company has a current ratio of 1.75, a quick ratio of 1.15 and a debt-to-equity ratio of 1.01. The company has a market cap of $2.80 billion, a price-to-earnings ratio of 16.63, a P/E/G ratio of 1.34 and a beta of 0.28.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, beating analysts' consensus estimates of $1.27 by $0.04. The firm had revenue of $338.97 million during the quarter, compared to the consensus estimate of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.Haemonetics's revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.19 earnings per share. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Research analysts expect that Haemonetics will post 4.55 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Haemonetics by 3.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier's stock worth $1,877,000 after purchasing an additional 971 shares during the last quarter. Caxton Associates LLP bought a new position in Haemonetics in the 1st quarter valued at $216,000. United Services Automobile Association acquired a new stake in shares of Haemonetics in the 1st quarter valued at $212,000. Empowered Funds LLC raised its position in shares of Haemonetics by 9.1% during the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier's stock worth $283,000 after acquiring an additional 372 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Haemonetics by 6.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier's stock valued at $9,923,000 after acquiring an additional 9,051 shares during the period. Institutional investors own 99.67% of the company's stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.